Published in Schizophr Bull on April 21, 2009
Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr Res (2011) 5.39
Rethinking schizophrenia. Nature (2010) 4.85
The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 4.16
At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry (2011) 3.66
The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr Res (2010) 2.78
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry (2010) 2.54
Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull (2012) 1.58
Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet (2013) 1.57
Self-experience in the early phases of schizophrenia: 5-year follow-up of the Copenhagen Prodromal Study. World Psychiatry (2011) 1.51
Subthreshold psychotic symptoms in 22q11.2 deletion syndrome. J Am Acad Child Adolesc Psychiatry (2014) 1.49
Are screening instruments valid for psychotic-like experiences? A validation study of screening questions for psychotic-like experiences using in-depth clinical interview. Schizophr Bull (2009) 1.49
Risk factors for psychosis: impaired social and role functioning. Schizophr Bull (2011) 1.43
Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. Schizophr Res (2010) 1.41
Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull (2009) 1.27
At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull (2012) 1.24
Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull (2014) 1.23
Identification and characterization of prodromal risk syndromes in young adolescents in the community: a population-based clinical interview study. Schizophr Bull (2011) 1.17
Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. Schizophr Bull (2011) 1.15
Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry (2011) 1.15
At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry (2015) 1.15
The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res (2010) 1.14
Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study. Schizophr Res (2013) 1.06
The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. Schizophr Bull (2015) 1.05
White matter microstructure in individuals at clinical high risk of psychosis: a whole-brain diffusion tensor imaging study. Schizophr Bull (2013) 1.04
Early and broadly defined psychosis risk mental states. Schizophr Res (2010) 1.01
Prevalence of attenuated psychotic symptoms and their relationship with DSM-IV diagnoses in a general psychiatric outpatient clinic. J Clin Psychiatry (2012) 1.00
Premorbid functional development and conversion to psychosis in clinical high-risk youths. Dev Psychopathol (2013) 0.99
Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions. Am J Psychiatry (2010) 0.97
Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol (2012) 0.97
Sexual dimorphisms and prediction of conversion in the NAPLS psychosis prodrome. Schizophr Res (2013) 0.95
Prevalence and clinical significance of DSM-5-attenuated psychosis syndrome in adolescents and young adults in the general population: the Bern Epidemiological At-Risk (BEAR) study. Schizophr Bull (2013) 0.92
Environmental Risk and Protective Factors and Their Influence on the Emergence of Psychosis. Adolesc Psychiatry (Hilversum) (2012) 0.91
Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011. Schizophr Res (2013) 0.90
Stigma of Mental Illness-1: Clinical reflections. Mens Sana Monogr (2012) 0.89
Error monitoring dysfunction across the illness course of schizophrenia. J Abnorm Psychol (2011) 0.88
"Attenuated psychotic symptoms syndrome" as a risk syndrome of psychosis, diagnosis in DSM-V: The debate. Indian J Psychiatry (2011) 0.88
Prodromal symptoms in adolescents with 22q11.2 deletion syndrome and schizotypal personality disorder. Schizophr Res (2011) 0.88
Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis. Schizophr Bull (2015) 0.87
Predicting the risk of psychosis onset: advances and prospects. Early Interv Psychiatry (2012) 0.87
Deficient Suppression of Default Mode Regions during Working Memory in Individuals with Early Psychosis and at Clinical High-Risk for Psychosis. Front Psychiatry (2013) 0.87
Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. Eur Child Adolesc Psychiatry (2016) 0.87
Should "risk syndrome for psychosis" be included as a diagnosis in DSM-V? World Psychiatry (2010) 0.86
Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention. Neuropsychiatry (London) (2012) 0.86
White matter development in the early stages of psychosis. Schizophr Res (2014) 0.86
Observations of a small sample of adolescents experiencing an at-risk mental state (ARMS) for psychosis. Schizophr Bull (2011) 0.85
Towards a Standard Psychometric Diagnostic Interview for Subjects at Ultra High Risk of Psychosis: CAARMS versus SIPS. Psychiatry J (2016) 0.84
Early prodromal symptoms can predict future psychosis in familial high-risk youth. J Psychiatr Res (2011) 0.83
The reliability and validity of the korean version of the structured interview for prodromal syndrome. Psychiatry Investig (2010) 0.83
Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium. Early Interv Psychiatry (2014) 0.82
Functional development in clinical high risk youth: prediction of schizophrenia versus other psychotic disorders. Psychiatry Res (2013) 0.81
A survey of psychosis risk symptoms in Kenya. Compr Psychiatry (2011) 0.80
When does cognitive decline occur in the period prior to the first episode of schizophrenia? Psychiatry (Edgmont) (2009) 0.79
Does a parent-report measure of behavioral problems enhance prediction of conversion to psychosis in clinical high-risk adolescents? Schizophr Res (2011) 0.79
Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study. Schizophr Bull (2013) 0.79
Self-reported cannabis use is inconsistent with the results from drug-screening in youth at ultra high-risk for psychosis in Colorado. Schizophr Res (2014) 0.79
Developmental mechanisms in the prodrome to psychosis. Dev Psychopathol (2013) 0.79
Prodromal research: Public health initiatives for prevention of schizophrenia. Indian J Psychiatry (2010) 0.78
The 'at-risk mental state' for psychosis in adolescents: clinical presentation, transition and remission. Child Psychiatry Hum Dev (2014) 0.78
Prodromal Symptom Severity Predicts Accelerated Gray Matter Reduction and Third Ventricle Expansion Among Clinically High Risk Youth Developing Psychotic Disorders. Mol Neuropsychiatry (2015) 0.78
Ultra high risk of psychosis on committal to a young offender prison: an unrecognised opportunity for early intervention. BMC Psychiatry (2012) 0.78
Severity of thought disorder predicts psychosis in persons at clinical high-risk. Schizophr Res (2015) 0.78
Schizotypy, psychotic-like experiences and distress: an interaction model. Psychiatry Res (2012) 0.78
Identifying children and adolescents at ultra high risk of psychosis in Italian neuropsychiatry services: a feasibility study. Eur Child Adolesc Psychiatry (2015) 0.78
Testing measurement invariance of the schizotypal personality questionnaire-brief scores across Spanish and Swiss adolescents. PLoS One (2013) 0.78
Anxiety in youth at clinical high risk for psychosis. Early Interv Psychiatry (2015) 0.77
Who is at risk for a psychotic disorder? Schizophr Bull (2009) 0.77
Current status specifiers for patients at clinical high risk for psychosis. Schizophr Res (2014) 0.77
The Psychosis Spectrum in 22q11.2 Deletion Syndrome Is Comparable to That of Nondeleted Youths. Biol Psychiatry (2016) 0.77
Interpersonal sensitivity and functioning impairment in youth at ultra-high risk for psychosis. Eur Child Adolesc Psychiatry (2015) 0.77
Reduced Amplitude of Low-Frequency Brain Oscillations in the Psychosis Risk Syndrome and Early Illness Schizophrenia. Neuropsychopharmacology (2016) 0.77
Co-morbidity of personality disorder in schizophrenia among psychiatric outpatients in China: data from epidemiologic survey in a clinical population. BMC Psychiatry (2016) 0.77
Stigma related to labels and symptoms in individuals at clinical high-risk for psychosis. Schizophr Res (2015) 0.77
CPA Treatment Guidelines for Individuals at Clinical High Risk of Psychosis. Can J Psychiatry (2017) 0.76
Disturbances of the Basic Self and Prodromal Symptoms Among Young Adolescents From the Community: A Pilot Population-Based Study. Schizophr Bull (2016) 0.76
Using human brain imaging studies as a guide toward animal models of schizophrenia. Neuroscience (2015) 0.76
Prophylactic valproic acid treatment prevents schizophrenia-related behaviour in Disc1-L100P mutant mice. PLoS One (2012) 0.76
The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions. Schizophr Res (2010) 0.76
Altered cognitive development in the siblings of individuals with schizophrenia. Clin Psychol Sci (2014) 0.76
Family Perception and 6-Month Symptomatic and Functioning Outcomes in Young Adolescents at Clinical High Risk for Psychosis in a General Population in China. PLoS One (2015) 0.75
Spatial analysis of schizotypal personality traits in Chinese male youths: evidence from a GIS-based analysis of Sichuan. Int J Ment Health Syst (2014) 0.75
Evaluation and treatment of children and adolescents with psychotic symptoms. Curr Psychiatry Rep (2012) 0.75
INCREASED INTERNET USE AND POORER ABILITY TO MANAGE EMOTIONS IN YOUTH AT HIGH-RISK FOR PSYCHOSIS. Schizophr Res Cogn (2015) 0.75
Transition to Psychosis: Evaluation of the First-Degree Relatives of Patients with Schizophrenia . Iran J Psychiatry (2016) 0.75
Common Measures for National Institute of Mental Health Funded Research. Biol Psychiatry (2016) 0.75
White matter alterations in individuals experiencing attenuated positive psychotic symptoms. Early Interv Psychiatry (2016) 0.75
Ethical and Epidemiological Dimensions of Labeling Psychosis Risk. AMA J Ethics (2016) 0.75
Cognitive behavioral therapy in prodromal psychosis. Curr Pharm Des (2012) 0.75
A critique of the "ultra-high risk" and "transition" paradigm. World Psychiatry (2017) 0.75
Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians. Harv Rev Psychiatry (2016) 0.75
Prediction and prevention of the first psychotic episode: new directions and opportunities. Ther Clin Risk Manag (2014) 0.75
The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis. Psychoneuroendocrinology (2017) 0.75
Identifying functional network changing patterns in individuals at clinical high-risk for psychosis and patients with early illness schizophrenia: A group ICA study. Neuroimage Clin (2017) 0.75
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry (1997) 41.93
Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry (2008) 9.54
Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry (1970) 8.51
Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull (2003) 7.11
Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry (1996) 5.71
A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med (2008) 5.61
Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry (2001) 5.35
Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry (2005) 5.17
Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry (2004) 4.74
Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry (2002) 4.60
The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry (1992) 4.54
Global assessment of functioning. A modified scale. Psychosomatics (1995) 4.48
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry (2006) 4.18
Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull (1982) 3.63
Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res (2004) 3.55
North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull (2007) 3.28
Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull (2007) 3.15
The diagnostic Interview for Personality Disorders: interrater and test-retest reliability. Compr Psychiatry (1988) 3.01
Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull (1996) 2.87
Strauss (1969) revisited: a psychosis continuum in the general population? Schizophr Res (2000) 2.74
The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull (2003) 2.67
Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry (2006) 2.60
Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch Gen Psychiatry (2005) 2.58
Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull (2007) 2.56
Screening for psychosis in the general population with a self-report interview. J Nerv Ment Dis (1991) 2.56
Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull (2005) 2.50
Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res (2008) 2.45
Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry (2000) 2.18
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry (2005) 2.03
The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol (2005) 2.00
A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr Res (2006) 1.81
Distributions of hallucinations in the population. Soc Psychiatry Psychiatr Epidemiol (1991) 1.80
Psychotic experiences in the general population: a twenty-year prospective community study. Schizophr Res (2007) 1.77
The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol (2005) 1.72
Depression in first-episode schizophrenia. Am J Psychiatry (1993) 1.71
Diagnostic stability in a Dutch psychosis incidence cohort. Br J Psychiatry (2004) 1.67
Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'. Schizophr Res (2004) 1.65
The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry (1993) 1.63
Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr Res (2003) 1.60
The Roscommon Family Study. IV. Affective illness, anxiety disorders, and alcoholism in relatives. Arch Gen Psychiatry (1993) 1.58
Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res (2004) 1.49
Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk". Schizophr Res (2005) 1.48
Factorial structure of the Scale of Prodromal Symptoms. Schizophr Res (2004) 1.47
The relations among putative biorisk markers in schizotypal adolescents: minor physical anomalies, movement abnormalities, and salivary cortisol. Biol Psychiatry (2006) 1.46
Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res (2006) 1.38
Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res (2006) 1.38
Psychotic-like experiences in nonpsychotic help-seekers: associations with distress, depression, and disability. Schizophr Bull (2005) 1.38
The assessment of "prodromal schizophrenia": unresolved issues and future directions. Schizophr Bull (2003) 1.36
Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr Bull (2005) 1.30
Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res (2006) 1.30
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res (2003) 1.29
Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. Schizophr Res (2007) 1.29
Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies. Schizophr Bull (2006) 1.26
Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatr Scand (2006) 1.24
How does studying schizotypal personality disorder inform us about the prodrome of schizophrenia? Curr Psychiatry Rep (2005) 1.24
Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull (2005) 1.24
The phenomenological critique and self-disturbance: implications for ultra-high risk ("prodrome") research. Schizophr Bull (2007) 1.16
Diagnostic stability of first-episode psychosis. Comparison of ICD-10 and DSM-III-R systems. Br J Psychiatry (1999) 1.15
Three-dimensional mapping of hippocampal anatomy in adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry (2008) 1.12
Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biol Psychiatry (2005) 1.10
The effects of race and comorbidity on clinical diagnosis in patients with psychosis. J Clin Psychiatry (1993) 1.10
Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res (2001) 1.09
Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur Psychiatry (2005) 1.08
The prevalence of prodromal features of schizophrenia in adolescence: a preliminary survey. Acta Psychiatr Scand (1995) 1.06
The Basel early-detection-of-psychosis (FEPSY)-study--design and preliminary results. Acta Psychiatr Scand (2007) 1.06
Axis-I disorders and vulnerability to psychosis. Schizophr Res (2004) 1.05
Biological, life course, and cross-cultural studies all point toward the value of dimensional and developmental ratings in the classification of psychosis. Schizophr Bull (2007) 1.02
A clinical approach to mild cognitive impairment. Am J Psychiatry (2006) 1.02
Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry (2005) 1.00
Validity of the premorbid adjustment scale. Schizophr Bull (2007) 1.00
Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res (2005) 1.00
First-episode psychosis: diagnostic stability over one and two years. Psychopathology (2008) 1.00
Comorbidity in psychosis at first hospitalization. Am J Psychiatry (1993) 0.99
Diagnostic stability in patients with first-episode psychosis. Australas Psychiatry (2005) 0.99
The "prodromal" patient: both symptomatic and at-risk. CNS Spectr (2001) 0.98
Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. J Clin Psychiatry (1998) 0.97
Early identification and high-risk strategies for bipolar disorder. Bipolar Disord (2007) 0.95
[Predictive validity of the Scale of Prodromal Symptoms (SOPS)]. Actas Esp Psiquiatr (2006) 0.95
Diagnostic stability over one year in first-episode psychosis. Schizophr Res (2006) 0.90
Schizotypal personality disorder or prodromal symptoms of schizophrenia? Schizophr Res (2005) 0.89
Prevalence and background factors of depression in first admitted schizophrenic patients. Acta Psychiatr Scand (2000) 0.87
Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. Arch Neurol (2004) 0.87
Psychiatric comorbidity in first episode schizophrenia: a 2 year, longitudinal outcome study. J Psychiatr Res (2006) 0.85
The Palau Early Psychosis Study: distribution of cases by level of genetic risk. Am J Med Genet B Neuropsychiatr Genet (2007) 0.85
The risk for psychiatric illness in siblings of schizophrenics: the impact of psychotic and non-psychotic affective illness and alcoholism in parents. Acta Psychiatr Scand (1996) 0.84
Childhood-onset schizotypal disorder: a follow-up study and comparison with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol (2005) 0.84
Time for a fresh start? Rethinking psychosis in DSM-V. Schizophr Bull (2007) 0.80
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Automatically parcellating the human cerebral cortex. Cereb Cortex (2004) 18.32
Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry (2010) 16.89
Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet (2009) 12.96
Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry (2008) 9.54
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull (2003) 7.11
Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet (2003) 6.63
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A (2009) 6.09
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry (2002) 4.60
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry (2006) 4.18
The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 4.16
Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia. Neuroimage (2004) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry (2011) 3.66
The Collaborative Longitudinal Personality Disorders Study (CLPS): overview and implications. J Pers Disord (2005) 3.51
Plausibility and possible determinants of sudden "remissions" in borderline patients. Psychiatry (2003) 3.29
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull (2007) 3.28
Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology (2009) 3.27
Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry (2008) 3.27
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry (2006) 3.17
Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull (2007) 3.15
Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am J Psychiatry (2003) 3.12
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry (2005) 3.08
Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. Am J Psychiatry (2002) 2.99
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Adolescent alcohol use is a risk factor for adult alcohol and drug dependence: evidence from a twin design. Psychol Med (2005) 2.66
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol (2005) 2.62
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry (2010) 2.54
The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull (2006) 2.53
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet (2006) 2.53
Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull (2005) 2.50
Cortical thinning of the attention and executive function networks in adults with attention-deficit/hyperactivity disorder. Cereb Cortex (2006) 2.44
Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry (2005) 2.43
Three potential susceptibility loci shown by a genome-wide scan for regions influencing the age at onset of mania. Am J Psychiatry (2004) 2.40
Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet (2005) 2.34
Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Arch Gen Psychiatry (2011) 2.33
Amygdala hyperreactivity in borderline personality disorder: implications for emotional dysregulation. Biol Psychiatry (2003) 2.31
Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol (2004) 2.30
Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A (2005) 2.29
Hierarchical genetic organization of human cortical surface area. Science (2012) 2.28
Hormonal cycle modulates arousal circuitry in women using functional magnetic resonance imaging. J Neurosci (2005) 2.25
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 2.22
Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am J Psychiatry (2005) 2.18
Axis I and axis II disorders as predictors of prospective suicide attempts: findings from the collaborative longitudinal personality disorders study. J Abnorm Psychol (2003) 2.17
Identification and treatment of a pineal region tumor in an adolescent with prodromal psychotic symptoms. Am J Psychiatry (2010) 2.12
Contributions of genetic risk and fetal hypoxia to hippocampal volume in patients with schizophrenia or schizoaffective disorder, their unaffected siblings, and healthy unrelated volunteers. Am J Psychiatry (2002) 2.08
Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci U S A (2007) 2.04
Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr Bull (2003) 2.04
Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry (2005) 2.03
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr Res (2009) 1.98
Implications for the neural basis of social cognition for the study of schizophrenia. Am J Psychiatry (2003) 1.98
Stability of functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder over two years. Psychol Med (2005) 1.97
Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. J Consult Clin Psychol (2004) 1.96